Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Jiangsu HengRui Medicine is the lead sponsor of 90 current clinical trials in our China, USA and UK registers. 54 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Trastuzumab Rezetecan, Zeprumetostat and FH-006. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

Recruiting5460%
Not yet open910%
Active, closed2730%

Trials by phase

Phase 32932%
Phase 22123%
Phase 1/21921%
Phase 11921%
Phase 2/311%
Phase 411%

Clinical trials sponsored by Jiangsu HengRui Medicine

90 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors NCT05473624 · Advanced Solid Tumors Drug: HRS-1167	Phase 1	Recruiting	2022-08	China
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer NCT07311694 · ClinicalTrials.gov ↗ · PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer	Phase 3	Recruiting	2026-02	China
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor NCT07140393 · ClinicalTrials.gov ↗ · Solid Tumor Drugs: Capecitabine, HRS-4508, Nab-paclitaxel	Phase 1/2	Recruiting	2025-10	China
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS NCT05277168 · Advanced Solid Tumors Drug: SHR-A1904	Phase 1/2	Recruiting	2022-05	USA
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications NCT07142980 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Harboring RAS Mutations or Amplifications Drug: HRS-7172	Phase 1	Recruiting	2025-09	China
A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis NCT06569056 · ClinicalTrials.gov ↗ · Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) Drug: HRS-8427	Phase 3	Recruiting	2024-09	China
A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection NCT07489482 · ClinicalTrials.gov ↗ · Diabetes Mellitus Drug: SHR-3167	Phase 1	Recruiting	2026-04	China
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer NCT06974929 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: HRS-2189, HRS-6209, Letrozole	Phase 1/2	Recruiting	2025-05	China
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma NCT07102901 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Drugs: SHR-1701, SHR-A1904, Trastuzumab Rezetecan	Phase 2	Recruiting	2025-09	China
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone NCT06689163 · ClinicalTrials.gov ↗ · Prostate Cancer Drugs: Abiraterone Acetate （II）, HRS-1167, Prednisone Acetate	Phase 1/2	Recruiting	2024-12	China
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma NCT06122389 · ClinicalTrials.gov ↗ · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy	Phase 3	Recruiting	2024-02	China
Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis NCT06775340 · ClinicalTrials.gov ↗ · Adolescent Asthma	Phase 2	Recruiting	2025-01	China
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer NCT07051486 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer Drug: Trastuzumab Rezetecan	Phase 2	Recruiting	2025-10	China
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia NCT07286032 · ClinicalTrials.gov ↗ · Patients With Chemotherapy-Induced Thrombocytopenia	Phase 3	Recruiting	2026-04	USA
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen NCT06123494 · ClinicalTrials.gov ↗ · HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	2024-01	China
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors NCT06598735 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	2024-11	China
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer NCT07238283 · ClinicalTrials.gov ↗ · First-line Treatment of Metastatic Pancreatic Cancer	Phase 3	Recruiting	2025-12	China
HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer NCT07232875 · ClinicalTrials.gov ↗ · KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting	Phase 3	Recruiting	2025-11	China
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer NCT07407283 · ClinicalTrials.gov ↗ · Prostate Cancer Drugs: HRS-5041, Rezvilutamide, Tazemetostat	Phase 1/2	Recruiting	2026-04	China
A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors NCT07070349 · ClinicalTrials.gov ↗ · Patients With Solid Tumors	Phase 1/2	Recruiting	2025-07	China
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors NCT07136142 · ClinicalTrials.gov ↗ · Malignant Solid Tumor Drug: FH-006	Phase 1/2	Recruiting	2025-09	China
A Study of SHR-A1811 in Subjects With Ovarian Cancer NCT06828354 · ClinicalTrials.gov ↗ · Ovarian Cancer Drugs: Doxorubicin Hydrochloride Liposome, Gemcitabine Hydrochloride, Paclitaxel	Phase 3	Recruiting	2025-03	China
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications NCT07189949 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Harboring RAS Mutations or Amplifications Drug: HRS-2329	Phase 1	Recruiting	2025-10	China
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC NCT04342910 · ClinicalTrials.gov ↗ · Gastric Cancer Drugs: Apatinib Mesylate, Camrelizumab, Irinotecan	Phase 3	Recruiting	2020-09	China
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors NCT07380334 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	2026-03	China
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer NCT07711184 · ClinicalTrials.gov ↗ · Prostate Cancer	Phase 1	Recruiting	2026-07	China
A Study of SHR-4394 Injection in Subjects With Prostate Cancer NCT06783829 · ClinicalTrials.gov ↗ · Prostate Cancer	Phase 1	Recruiting	2025-01	China
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC NCT04316364 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer	Phase 3	Recruiting	2020-07	China
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer NCT05482568 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer	Phase 1/2	Recruiting	2022-09	China
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. NCT06015048 · ClinicalTrials.gov ↗ · HER2-expressing Advanced Solid Tumors	Phase 1/2	Recruiting	2023-08	China
Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations NCT07134998 · ClinicalTrials.gov ↗ · Advanced KRAS G12D Mutant Solid Tumors	Phase 1	Recruiting	2025-09	China
A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery NCT06529432 · ClinicalTrials.gov ↗ · Local Analgesia Via Nerve Block Drugs: Bupivacaine hydrochloride, Bupivacaine liposome	Phase 2	Recruiting	2026-03	China
A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes NCT07032688 · ClinicalTrials.gov ↗ · Type 2 Diabetes Drugs: Insulin Degludec, SHR-3167	Phase 1	Recruiting	2025-08	China
A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT07232849 · ClinicalTrials.gov ↗ · Lung Cancer Drug: HRS-4508	Phase 2	Recruiting	2025-12	China
A Trial of HRS-6768 in Patients With Advanced Solid Tumors NCT06925581 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	2025-04	China
A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo NCT07251595 · ClinicalTrials.gov ↗ · Non-segmental Vitiligo	Phase 2	Recruiting	2025-12	China
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients NCT06555068 · ClinicalTrials.gov ↗ · Advanced Unresectable or Metastatic Breast Cancer Drugs: Fulvestrant, HRS-1358, HRS-6209	Phase 1/2	Recruiting	2024-08	China
A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia NCT06841731 · ClinicalTrials.gov ↗ · Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) Drugs: HRS-8427, Meropenem	Phase 2	Recruiting	2025-04	China
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT07003321 · ClinicalTrials.gov ↗ · Solid Tumor Drug: HRS-4508	Phase 2	Recruiting	2025-09	China
A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients NCT06344091 · ClinicalTrials.gov ↗ · Local Analgesia Via Infiltration	Phase 4	Recruiting	2024-05	China
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer NCT06568094 · ClinicalTrials.gov ↗ · Prostate Cancer Drugs: Abiraterone Acetate （II）, Docetaxel, HRS-1167	Phase 1/2	Recruiting	2024-09	China
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer NCT07497386 · ClinicalTrials.gov ↗ · Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer Drugs: Trastuzumab deruxtecan, Trastuzumab Rezetecan	Phase 2	Recruiting	2026-04	China
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors NCT06520488 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Drug: HRS-4642	Phase 1/2	Recruiting	2024-08	China
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer NCT07241767 · ClinicalTrials.gov ↗ · Lung Cancer Drugs: Adebrelimab, BP102, Carboplatin	Phase 2	Recruiting	2025-11	China
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer NCT07241416 · ClinicalTrials.gov ↗ · Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Drugs: Enzalutamide Soft, Rezvilutamide	Phase 3	Recruiting	2025-12	China
Phase I Study of HRS-3005 in B-cell Malignancies NCT07556822 · ClinicalTrials.gov ↗ · B-cell Malignancy	Phase 1	Recruiting	2026-06	China
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. NCT05884255 · ClinicalTrials.gov ↗ · Advanced Gastroenteropancreatic Neuroendocrine Tumor	Phase 3	Recruiting	2023-07	China
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer NCT07230106 · ClinicalTrials.gov ↗ · Prostate Cancer Drugs: Abiraterone, Enzalutamide, HS-20093	Phase 2	Recruiting	2025-12	China
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects NCT07175220 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Non-small Cell Lung Cancer Drugs: SHR-1701, SHR-A2102, Zeprumetostat	Phase 2	Recruiting	2025-10	China
A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects NCT07446153 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	2026-03	China
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations NCT06430437 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer With HER2- Mutations	Phase 3	Recruiting	2024-07	China
The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia NCT07362355 · ClinicalTrials.gov ↗ · Primary Gout and Hyperuricemia	Phase 2	Recruiting	2026-02	China
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT05942001 · ClinicalTrials.gov ↗ · Advanced Prostate Cancer Drugs: Abiraterone acetate, Docetaxel, Enzalutamide Soft	Phase 1	Recruiting	2023-08	China
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors NCT06735144 · ClinicalTrials.gov ↗ · Malignant Solid Tumor Drug: FH-006	Phase 1/2	Recruiting	2024-12	China
Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults NCT07746726 · ClinicalTrials.gov ↗ · Neuromuscular Blockade	Phase 3	Not yet open	2026-08	China
Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients NCT07056439 · ClinicalTrials.gov ↗ · PET Imaging in Patients With Prostate Cancer	Phase 1/2	Not yet open	2025-07	China
A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis NCT07102888 · ClinicalTrials.gov ↗ · Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents Drug: RSS0393	Phase 2	Not yet open	2025-08	China
FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. NCT07790380 · ClinicalTrials.gov ↗ · Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy Drug: FH-006	Phase 3	Not yet open	2026-10	China
A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions NCT06731829 · ClinicalTrials.gov ↗ · For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions Drug: Gadobutrol	Phase 2	Not yet open	2024-12	China
A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2 NCT07796763 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer Expressing HER2	Phase 2	Not yet open	2026-11	USA
A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors NCT06906731 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Not yet open	2025-04	China
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma NCT06368167 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Phase 2	Not yet open	2024-04	China
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors NCT07806058 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drugs: Adebrelimab, HRS-4642, HRS-7172	Phase 1/2	Not yet open	2026-09	China
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer NCT04691804 · Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug: Fluzoparib	Phase 3	Active, closed	2021-03	UK, USA, China
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial NCT05814354 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Trastuzumab Rezetecan	Phase 3	Active, closed	2023-06	China
A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer NCT05945901 · ClinicalTrials.gov ↗ · Colorectal Cancer Drug: HR070803	Phase 2/3	Active, closed	2023-08	China
A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants NCT07610148 · ClinicalTrials.gov ↗ · Breast Cancer Drug: HRS-6209	Phase 1	Active, closed	2026-06	China
Extension Study of Hetrombopag in Severe Aplastic Anemia NCT04961710 · ClinicalTrials.gov ↗ · Treatment-naive Severe Aplastic Anemia Drug: Hetrombopag Olamine	Phase 3	Active, closed	2019-09	China
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy NCT06126640 · ClinicalTrials.gov ↗ · HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Drugs: Trastuzumab emtansine, Trastuzumab Rezetecan	Phase 3	Active, closed	2023-11	China
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation NCT04639180 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC) Drugs: Apatinib, Camrelizumab, Rivoceranib	Phase 3	Active, closed	2021-04	China
Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects NCT06308393 · ClinicalTrials.gov ↗ · Healthy, Psoriatic Subjects	Phase 1	Active, closed	2024-03	China
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. NCT05864014 · ClinicalTrials.gov ↗ · Chemotherapy-Induced Thrombocytopenia Drug: Hetrombopag	Phase 3	Active, closed	2023-04	China
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer NCT03980054 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Pyrotinib	Phase 3	Active, closed	2019-07	China
A Trial of SHR0302Base in Patients With Vitiligo NCT06790862 · ClinicalTrials.gov ↗ · Vitiligo	Phase 2	Active, closed	2025-02	China
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma NCT05320692 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: Apatinib Mesylate, Camrelizumab, TACE	Phase 3	Active, closed	2022-08	China
Study on the Mass Balance of [14C]HRS-9190 for Injection in Healthy Participants NCT07494175 · ClinicalTrials.gov ↗ · Healthy Adult Male	Phase 1	Active, closed	2026-04	China
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors NCT05781048 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Active, closed	2023-03	China
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer NCT04906993 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Active, closed	2021-07	China
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer NCT07196774 · ClinicalTrials.gov ↗ · Early-stage or Locally Advanced HER2-positive Breast Cancer Drugs: Carboplatin, Docetaxel, Pertuzumab	Phase 3	Active, closed	2025-10	China
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation NCT06385678 · ClinicalTrials.gov ↗ · Advanced KRAS G12D Mutant Solid Tumors Drugs: Adebrelimab, Cetuximab, HRS-4642	Phase 1/2	Active, closed	2024-07	China
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer NCT06057610 · ClinicalTrials.gov ↗ · HER2-PositiveRecurrent or Metastatic Breast Cancer	Phase 3	Active, closed	2023-11	China
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs NCT07018453 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus Drugs: Insulin Degludec, SHR-3167	Phase 2	Active, closed	2025-07	China
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer NCT06413745 · ClinicalTrials.gov ↗ · HER2 Expression / Amplification in Patients With Biliary Tract Cancer Drug: Trastuzumab Rezetecan	Phase 2	Active, closed	2024-06	China
Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative NCT04842617 · ClinicalTrials.gov ↗ · Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer Drug: Dalpiciclib	Phase 3	Active, closed	2021-04	China
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms NCT03603951 · ClinicalTrials.gov ↗ · Relapsed or Refractory Mature Lymphoid Neoplasms Drug: Zeprumetostat	Phase 1	Active, closed	2018-08	China
Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation NCT05533463 · ClinicalTrials.gov ↗ · Advanced KRAS G12D Mutant Solid Tumors Drug: HRS-4642	Phase 1	Active, closed	2022-09	China
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane NCT05424835 · ClinicalTrials.gov ↗ · HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Drugs: Capecitabine, Pyrotinib, Trastuzumab Rezetecan	Phase 3	Active, closed	2022-08	China
A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents NCT07472725 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2	Phase 2	Active, closed	2026-04	China
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis NCT04957550 · ClinicalTrials.gov ↗ · Psoriatic Arthritis	Phase 3	Active, closed	2021-08	China
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma NCT05363800 · ClinicalTrials.gov ↗ · Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma	Phase 1	Active, closed	2022-06	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Jiangsu HengRui Medicine trials

66 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 26 more in the trial list above.

Conditions in Jiangsu HengRui Medicine trials

75 conditions

Advanced Solid Tumors7 Prostate Cancer6 Breast Cancer4 Solid Tumor3Advanced KRAS G12D Mutant Solid Tumors3Advanced Solid Tumors Harboring RAS Mutations or Amplifications2Malignant Solid Tumor2Lung Cancer2 Metastatic Castration-Resistant Prostate Cancer (mCRPC)1Patients With Chemotherapy-Induced Thrombocytopenia1Advanced Colorectal Cancer Expressing HER21PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer1Colorectal Cancer1Treatment-naive Severe Aplastic Anemia1Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)1Neuromuscular Blockade1Diabetes Mellitus1 Advanced Gastric Cancer1Metastatic Gastric Cancer1Gastroesophageal Junction Adenocarcinoma1HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy1Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy1Adolescent Asthma1Hepatocellular Carcinoma (HCC)1

By trial register

Register	Trials	Recruiting
Clinical trials in China	87	52
Clinical trials in USA	4	2
Clinical trials in UK	1	0

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Advanced Solid Tumors

Sponsor	Trials
Sichuan Kelun-Biotech Biopharmaceutical	9
Suzhou Suncadia Biopharmaceuticals	7
Shanghai Hengrui Pharmaceutical	6
Bristol-Myers Squibb	5
MediLink Therapeutics (Suzhou)	5
Hangzhou Zhongmei Huadong Pharmaceutical	5
Hansoh BioMedical R&D Company	4
Bayer	3
Vividion Therapeutics	3
Multitude Therapeutics	3

Sponsors with the most current trials registered for this condition.

Questions about Jiangsu HengRui Medicine trials

How many clinical trials does Jiangsu HengRui Medicine sponsor?

Jiangsu HengRui Medicine is the lead sponsor of 90 current trials on ClinicalTrials.gov in our China, USA and UK registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Jiangsu HengRui Medicine trials recruiting?

Yes. 54 of its 90 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Jiangsu HengRui Medicine testing?

Its current trials name 66 drugs and biologicals as interventions. The most frequent are Trastuzumab Rezetecan (10), Zeprumetostat (5), FH-006 (4), HRS-4642 (4) and Adebrelimab (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Jiangsu HengRui Medicine clinical trials